Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Neurochemical modulation of executive and memory functions
2005-000434-21Phase 2Active
- Sponsor
- Forschungszentrum Jülich
- Start
- Nov 2006
- Modality
- Small Molecules, Metabolically Activated Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules, Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2 trial of XI Ning, physostigmine, glycopyrronium, levodopa and carbidopa in aging-related decline, Dysexecutive Syndrome (DES), dysmnesia and 3 more, sponsored by Forschungszentrum Jülich. Primary endpoint: BOLD-effect. Started Nov 2006; status: active.
02
Drugs
XI Ningphysostigmineglycopyrroniumlevodopacarbidopa
03
Conditions
aging-related declineDysexecutive Syndrome (DES)dysmnesiaDementiaParkinson's disease (PD)
Beyond the preview
Go deeper on 2005-000434-21.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2005-000434-21.